AtriCure, Inc. (ATRC)

AtriCure, Inc.'s Q·Score is 6.5/10 (Neutral), reflecting its current fundamentals, analyst data, and valuation metrics. Clean balance sheet with low leverage (0.1× debt-to-equity). Key area to monitor: low return on equity (2%). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for ATRC is $47.33, based on ratings from 9 Wall Street analysts. This is 25.4% above the current price of $37.76. Price targets are forward-looking estimates and not guarantees of future performance.

AtriCure, Inc. (ATRC) scores in line with sector averages on valuation metrics. Its forward P/E ratio stands at 87.4×. The consensus analyst price target of $47.33 is 25% above the current price.

AtriCure, Inc.'s next earnings report is expected on approximately October 27, 2026.

AtriCure, Inc. has a net profit margin of 1.9%, which is positive but relatively thin. Its gross margin stands at 76.3%, indicating a high-margin business model.

AtriCure, Inc. is reporting solid revenue growth of 12.8% year-over-year.

AtriCure, Inc. has a debt-to-equity ratio of 0.14×, reflecting a very low debt-to-equity ratio, signalling a conservatively financed balance sheet. Its current ratio is 4.22×, indicating comfortable short-term liquidity.